NIKKEI 225
38,837.46 -85.54 (-0.22%) HANG SENG
18,444.11 +41.11 (+0.22%) CRUDE OIL
73.31 -0.91 (-1.23%) GOLD FUTURES
2,346.50 -22.80 (-0.96%) DOW
38,634.33 +63.30 (+0.16%) Bitcoin GBP
55,178.13 +1,091.62 (+2.02%)
PFE Jul 2024 22.000 call
| Previous close | 6.16 |
| Open | 6.16 |
| Bid | 7.55 |
| Ask | 7.85 |
| Strike | 22.00 |
| Expiry date | 2024-07-19 |
| Day's range | 6.16 - 6.17 |
| Contract range | N/A |
| Volume | |
| Open interest | 7 |
- Yahoo Finance Video
FDA considers updating COVID boosters, Novavax stock reacts
The US Food and Drug Administration (FDA) is set to vote on recommendations for updated COVID-19 booster shots as the KP.2 variant strain begins to spread across the US. Yahoo Finance Health Reporter Anjalee Khemlani joins Market Domination to discuss the impact this is having on vaccine makers, particularly Novavax (NVAX), whose stock has shot up in Monday's session. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Luke Carberry Mogan.
BenzingaPromising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
On Friday, Pfizer Inc (NYSE: PFE) revealed its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial. On Monday, Moderna (NASDAQ: MRNA) and Merck & Co (NYSE: MRK) also reported durable efficiency of their combined melanoma treatment that consists of an experimental mRNA vaccine and Merck’s blockbuster immunotherapy, Keytruda. Pfizer Is Aiming To Set The Treatment Standard For Lung Cancer With encouraging results, Pfizer is getting another step closer t
ZacksFDA Panel to Consider Updating COVID-19 Jabs for New Virus Strains
An FDA panel meeting is scheduled on Jun 5 to consider if COVID-19 vaccines should be updated to target the WHO-recommended JN.1 variant or the KP.2 variant which is the currently dominating strain in the country.
